Robotic-Assisted Radical Cystectomy: Single-Center Analysis of Factors Impacting Clavien ≥ II Complications.

IF 1.7 Q2 MEDICINE, GENERAL & INTERNAL
Maria Chiara Sighinolfi, Tommaso Calcagnile, Enrico Panio, Simone Assumma, Luca Sarchi, Marco Sandri, Emanuela Santangelo, Michele Petix, Mattia Sangalli, Filippo Turri, Giorgio Bozzini, Marcio Covas Moschovas, Vipul Patel, Bernardo Rocco
{"title":"Robotic-Assisted Radical Cystectomy: Single-Center Analysis of Factors Impacting Clavien ≥ II Complications.","authors":"Maria Chiara Sighinolfi, Tommaso Calcagnile, Enrico Panio, Simone Assumma, Luca Sarchi, Marco Sandri, Emanuela Santangelo, Michele Petix, Mattia Sangalli, Filippo Turri, Giorgio Bozzini, Marcio Covas Moschovas, Vipul Patel, Bernardo Rocco","doi":"10.3390/clinpract14050143","DOIUrl":null,"url":null,"abstract":"<p><p>Despite the advent of robotics and the decreasing rate of complications after radical cystectomy, several factors are renowned to impair the early outcomes of this procedure. The aim of this paper is to provide a multivariate analysis (MVA) of patient and surgical procedure-related variables likely to affect postoperative course and 30-day complication rate. Fifty-five robotic-assisted radical cystectomies (RARCs) performed at a single center from July 2021 to March 2023 were enrolled. Baseline demographics, comorbidities, and intraoperative and postoperative data were collected. Uni- and multivariate analyses were performed to evaluate the relationship with Clavien ≥ II complications arising within 30 days of surgery. A postoperative Clavien ≥ II complication was evident in 15 patients (28%), whereas Clavien ≥ III occurred only in 5 (9%). At MVA, the only independent predictor of Clavien ≥ II complications was a prior neoadjuvant chemotherapy (OR 5.6; 95% CI 1.22-25.3, <i>p</i> = 0.026). Recognized the small sample size, patients who received a prior NAC should deserve special care within the postoperative course.</p>","PeriodicalId":45306,"journal":{"name":"Clinics and Practice","volume":"14 5","pages":"1790-1800"},"PeriodicalIF":1.7000,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11417726/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinics and Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/clinpract14050143","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Despite the advent of robotics and the decreasing rate of complications after radical cystectomy, several factors are renowned to impair the early outcomes of this procedure. The aim of this paper is to provide a multivariate analysis (MVA) of patient and surgical procedure-related variables likely to affect postoperative course and 30-day complication rate. Fifty-five robotic-assisted radical cystectomies (RARCs) performed at a single center from July 2021 to March 2023 were enrolled. Baseline demographics, comorbidities, and intraoperative and postoperative data were collected. Uni- and multivariate analyses were performed to evaluate the relationship with Clavien ≥ II complications arising within 30 days of surgery. A postoperative Clavien ≥ II complication was evident in 15 patients (28%), whereas Clavien ≥ III occurred only in 5 (9%). At MVA, the only independent predictor of Clavien ≥ II complications was a prior neoadjuvant chemotherapy (OR 5.6; 95% CI 1.22-25.3, p = 0.026). Recognized the small sample size, patients who received a prior NAC should deserve special care within the postoperative course.

机器人辅助根治性膀胱切除术:影响 Clavien ≥ II 并发症因素的单中心分析。
尽管机器人技术的出现降低了根治性膀胱切除术后的并发症发生率,但仍有几个因素会影响该手术的早期疗效。本文旨在对可能影响术后疗程和30天并发症发生率的患者和手术过程相关变量进行多变量分析(MVA)。本文纳入了 2021 年 7 月至 2023 年 3 月期间在一个中心进行的 55 例机器人辅助根治性膀胱切除术(RARC)。收集了基线人口统计学、合并症、术中和术后数据。进行了单变量和多变量分析,以评估与术后30天内出现的Clavien≥II并发症的关系。15 名患者(28%)出现了明显的术后 Clavien ≥ II 并发症,而 Clavien ≥ III 仅发生在 5 名患者(9%)身上。在MVA时,Clavien≥II并发症的唯一独立预测因素是之前的新辅助化疗(OR 5.6;95% CI 1.22-25.3,P = 0.026)。尽管样本量较小,但曾接受过新辅助化疗的患者在术后应得到特别护理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinics and Practice
Clinics and Practice MEDICINE, GENERAL & INTERNAL-
CiteScore
2.60
自引率
4.30%
发文量
91
审稿时长
10 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信